Market Research Reports
Drugs of Abuse Testing Market is Expected to Reach USD 3.4 Billion Globally in 2018: Transparency Market Research
According to a new market report published by Transparency Market Research “Drugs of Abuse Testing Market (Sample Based Testing – Urine, Saliva and Hair Onsite and laboratory Testing) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2018” the global drugs of abuse testing market was valued at USD 2.6 billion in 2012 and is expected to grow at a CAGR of 4.8% from 2013 to 2018, to reach an estimated value of USD 3.4 billion in 2018.
Browse the full Report with TOC: http://www.transparencymarketresearch.com/drugs-abuse-testing-market.html
In various countries, government rules & regulations are supporting drugs of abuse testing market to grow, as they have outlined essential drug testing at workplace, such as in the US, Japan, Australia and the UK. As a result, this market is expected to grow at a CAGR of about 4.8% during 2013 – 2018.
Some of the key driving factors for the drugs of abuse testing market are global rising consumption of illicit drugs, adoption of drug of abuse (DOA) testing at organizational level, increased production of illicit drugs and their trade and increasing death rates/road accidents due to drug abuse. However, the market faces some restraints such as social concerns associated with illicit drugs testing, legalization of various drugs, and economic volatility and cost concerns.
North America, including the US has the largest drugs of abuse testing market and is also the fastest growing drugs of abuse testing market. Some of the fastest growing markets for drugs of abuse testing are US, UK, Japan, Germany and other European countries. According to UNODC report 2013, number of illicit drug users is estimated to increase from 167 million in 2009 to 315 million people in 2011. This corresponds to 3.6% to 6.9% of global adult population and cannabis, opioids and opiates were most commonly used illicit drugs. In various countries, including America and Europe countries, organizations are conducting drug screening test at various levels, such as pre-employment screening, random drug/alcohol screening, post incident drug/alcohol screening and abstinence monitoring. In many countries, government rules & regulations are also supporting the growth of drugs of abuse testing market, as they have outlined essential drug testing at workplace, such as in the US, Japan, Australia and the UK. This has emerged as a key driver for the market.
Urine is the largest sample which is diagnosed in the drugs of abuse testing market and it is expected to grow at a CAGR of about XX% during 2013 – 2018. The other major samples for drugs of abuse testing are Saliva and Hair. Laboratory drug screening test requires a trained and skilled person to provide an accurate result and involves in-depth analysis. In laboratory screening test, usually the test is reconfirmed using gas chromatography/mass spectrometry or any other superior techniques to provide accurate results. On-site drug screening test gives results on the spot and it is generally preferred for those who take the drug test at home, workplace and educational institutions. The most common specimens used in on-site drug testing are urine, saliva and hair. Nowadays, commercially-available on-site screening test kits are usually designed for urine and saliva specimens only.
Roche Diagnostics is the leading player in the global drugs of abuse testing market. Other major players of drugs of abuse testing market include Quest Diagnostics, LabCorp, Alere and Abbott Laboratories and others.
The global drugs of abuse testing market is segmented as follows:
Drugs of Abuse Testing Market, By Sample
Drugs of Abuse Testing Market, By Types
- Laboratory Drug Test
- On-site Screening Test
Drugs of Abuse Testing Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
According to a new market report published by Transparency Market Research “Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti allergy/ inflammatory/ infective, Retinal Drugs) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2018” the global ophthalmic drugs market was valued at USD 16 billion in 2012 and is expected to grow at a CAGR of 5.2% from 2013 to 2018, to reach an estimated value of USD 21.6 billion in 2018.
Browse the full Report with TOC: http://www.transparencymarketresearch.com/ophthalmic-drugs-market.html
Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 – 2018.
Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China), technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases. However, the market faces some restraints such as lack of awareness among people regarding eye disorders, drying pipeline of ophthalmic drugs, patent expiration of blockbuster ophthalmic drugs and absence of health insurance in developing countries.
North America, including the US has the largest ophthalmic drugs market. Asia is the fastest growing ophthalmic drugs market. Some of the fastest growing markets for ophthalmic drugs are China, India, other countries in South East Asia and the Eastern Mediterranean. As per WHO estimates in 2010, in the next nine years, the number of blind people aged 50 years and above will grow in these regions, thereby increasing the demand for ophthalmic drugs. On the other hand, in developed regions such as North America and Western Europe, rising efforts towards prevention of blindness among the aging population has emerged as a key driver for the market.
Browse full PDF with TOC: Ophthalmic Drugs Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2018
Glaucoma has the largest market share in the ophthalmic drugs market and it is expected to grow at a CAGR of about 4.2% during 2013 – 2018. Various ophthalmic drug companies are increasing their focus on combination therapy, which involves use of more than one medication for specific retinal disorders. Most of these combination therapies are used as first line treatment in patients with high level of intraocular pressure. Combination therapy has various advantages over traditional medication such as reduced frequency of eye drop application, improved patient compliance and efficacy.
Novartis (Alcon) is the leading player in the global ophthalmic drugs market while other major players include Allergan, Santen, Pfizer, Merck and Roche.
The global ophthalmic drugs market is segmented as follows:
Ophthalmic Drugs Market, By Treatment Drugs
- Dry Eye Drugs
- Retinal Drugs
- Anti-inflammatory/allergy/infective Drugs
- Anti-glaucoma Drugs
Ophthalmic Drugs Market, By Types
- Prescription Drugs
- OTC Drugs
Ophthalmic Drugs Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
Browse more market research reports: Transparency Market Research
Released New Report: Global Equine Healthcare Market is Expected to Reach USD 24.5 Billion in 2019: Transparency Market Research
According to a new market report published by Transparency Market Research “Equine Healthcare Market (Diagnostic Products, Therapeutic Products and Supplement Products) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019″ the global equine healthcare market was valued at USD 26.6 billion in 2012 and is expected to decline at a CAGR of -1.2% from 2013 to 2019, to reach an estimated value of USD 24.5 billion in 2019.
Browse the full report with complete TOC: http://www.transparencymarketresearch.com/equine-healthcare-market.html
The equestrian industry results in a substantially high economic impact as a result of one of the industry’s primary activity – horse racing and betting; horse racing and betting comprises ~20% share of the global betting/gambling market. The equestrian industry thus generates a multiplier effect resulting into turnover of over ~USD 500 billion per year. Due to the ‘trickle-down effect’ of flow of the economic impact of the overall equestrian industry, multiple support or secondary markets exist and sustain; the equine healthcare market is among such support or secondary markets. As the base of existence of the equestrian industry is the population/number of horses worldwide, any change in the equine population impacts the equestrian industry and the support or secondary markets such as the equine healthcare market. Many experts and corroborating statistical data reveals that the global equine population is expected to decline over the years till 2019; consequentially, the equine healthcare market too is expected to decline by 1.2% over six years, from 2013 to 2019, to reach an estimated value of USD 24,527.8 million in 2019.
Equine healthcare market comprises of various ‘product market segments’ in context of various products used for treatment of equine-specific healthcare conditions, diagnosis of equine-specific healthcare conditions and also supplements and protection products used for upkeep and maintenance of a horse. Thus the three prime segments of the equine healthcare market are equine diagnostic products, equine therapeutic products and equine supplement products.
In context of equine (pregnancy and gestation) diagnostic products, there are two key categories of products used namely UltraSound devices and equine urine test kits. Of the two categories, equine urine test kits are affordable and easy-to-use and interpret the results and also help overcome a prime limitation of UltraSound devices i.e. the kits are non-invasive in nature. Thus, we expect equine urine test kits to be increasingly preferred by the veterinarians and the end-users, going forward. Also, the equine urine test kit is a unique product to the equine species and cannot be substituted by the urine test kits for humans. Therefore, we estimate the urine test kits market to be a niche opportunity that is likely to be encashed by newer entrants thus expanding the market and driving growth of the equine diagnostic products market.
In terms of geographical markets of the equine healthcare market, the Asia-Pacific region is touted to be the ‘next growth story’. A constituent of Asia-Pacific namely the Australian market is among the leading ‘horse producing/breeding’ countries. Additionally, China is expanding capacity and investing in horse racing and betting by importing quality breeds from other countries. China is thus intent on maintaining particularly race-horse breeds. As race-horses require additional and specific supplement and protection products, therapeutic and also diagnostic products, sales of all these products is thus expected to be high in the Asia-Pacific market. Therefore the afore-mentioned factors are likely to drive growth of the Asia-Pacific market.
The global equine healthcare market is segmented as follows:
Equine Diagnostic Products Market, by Type
- Equine Pregnancy and Gestation Diagnostic Products Market
- Equine Genotype Analysis Products Market
Equine Therapeutics Product Market, by Type
- Equine Vaccines Market
- Equine Antibacterials Market
- Equine Antivirals Market
- Equine Antiprotozoals/Dewormers Market
- Equine Dopamine Agonists Market
- Equine Anti-inflammatory Drugs Market
- Equine Laxatives Market
Equine Supplement Products Market, by Type
- Equine Performance Supplement Market
- Equine Protection Products Market
- Equine Prosthetics Market
Equine Healthcare Market, by Geography
- North America
- Rest of World (RoW)
The biotechnology market is expected to show substantial growth over the forecast period owing to regulatory support offered to various companies operating in the biotechnology field. In addition, the increased demand for food in developing countries has spurred the growth of the bioagriculture market. Bioseeds are expected to show exponential growth as compared to conventional seeds over the forecast period.
Browse the full report: http://www.transparencymarketresearch.com/biotechnology-market.html
This report on the biotechnology market analyzes and estimates the global revenue generated by the biotechnology industry over the forecast period i.e. 2012 to 2017. The scope of the report considers biotechnology to be divided into four primary segments namely biopharmacy, bioservices, bioagriculture and bioindustrial. In terms of technology, the biotechnology market has been segmented into fermentation, tissue regeneration, PCR technology, nanobiotechnology, chromatography, DNA sequencing, cell based assay and others. The others segment comprises of genetic engineering, enzyme technology and fingerprinting among others.
Browse the full PDF with TOC:Biotechnology_Market_-_Global_Industry_Analysis__Size__Share__Growth__Trends_And_Forecast__2012_-_2018
Biopharmacy comprises of various pharmaceuticals manufactured by using biotechnology and also covers medical devices. The bioservices segment predominantly comprises of CROs (Contract Research Organizations) which are third party organizations performing clinical trials, drug discovery and contract manufacturing. The bioindustrial application includes the use of bioenzymes and biochemicals for a variety of chemical processes. Bioagriculture comprises of bioseeds and genetically modified (GM) crops.
The study explains the various drivers and restraints affecting the market along with the impact they would have over the forecast period. A detailed analysis of the opportunities available in the market over the next five years has also been included. The value chain for the biotechnology market has been provided for a better understanding of the process followed in the market. The study covers in detail the Porters Five Forces analysis, which gives the users of this report a better perspective into the present and future market scenarios. The market has been segmented based on technology, application and geography. Apart from the global application overview, the report further segregates the applications for regions such as North America, Europe, Asia Pacific and Rest of the World (RoW).
Key market players in the report include Roche, Amgen, Novo Nordisk, Sanofi and Pfizer among others. A detailed company market share has been included to give a better understanding of the competitive situation in the market. In addition, these companies have been profiled with respect to attributes such as company overview, financial overview, SWOT analysis, business strategy and recent developments.
Biotechnology Market, by Technology:
- Tissue regeneration
- PCR technology
- DNA sequencing
- Cell based assay
Biotechnology Market, by Application:
The report provides a cross-sectional analysis of all the above applications with respect to the following geographical markets:
- North America
- Asia Pacific
- Rest of the World (RoW)
The detailed analysis and research will help biotechnology companies, retailers and R&D institutes to make well-informed decisions about manufacturing, marketing and sales and in turn help them gain competitive advantage.
- Transcriptomics Technologies Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019 (usamarketresearch.wordpress.com)